Symphony Financial 13F: Adds $1.3M to Cardinal Health (CAH) Stake
Key Points
- Symphony Financial increased its Cardinal Health, Inc. CAH holdings by 5,991 shares to end with 9,615 shares worth about $2.1 million, according to an October 22, 2026 filing.
- Cardinal Health, Inc. recently traded around $255.64, holding a market value of roughly $59.3 billion and heading toward its next earnings report on November 5, 2026.
- Analyst firms including UBS and Mizuho recently adjusted their outlooks on the healthcare distributor, which carries a consensus buy rating.
Get Cardinal Health text alerts
We text you when insiders, Congress, analysts or big funds move on $CAH.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Cardinal Health, Inc. alert may contain errors. Disclosures
Symphony Financial grew its holdings in Cardinal Health, Inc. CAH by 165.3% during the period, purchasing an additional 5,991 shares. According to a Form 13F filing with the SEC on October 22, 2026, the firm ended the period with 9,615 shares valued at approximately $2.1 million. The fund held 3,624 shares previously.
CAH
Cardinal Health, Inc.
Symphony Financial vs. the S&P 500
Hypothetical returns from Symphony Financial's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Cardinal Health
Other large investors have adjusted their positions in the medical products and distribution company as well. Traphagen Investment Advisors opened a brand-new stake, ending with 992 shares worth about $220,729. Meanwhile, HSBC Holdings reduced its holdings by 92,629 shares to finish with 519,844 shares valued at roughly $123.5 million. Janus Henderson Group grew its stake significantly by 559,450 shares, bringing its total to 735,467 shares worth about $175.0 million. Natixis Advisors trimmed its position by 28,419 shares, leaving it with 492,832 shares valued at approximately $117.1 million. Intech Investment Management cut its holdings by 62,358 shares, ending with 146,183 shares worth about $34.7 million.
Cardinal Health, Inc. Stock Up 1.2%
Cardinal Health, Inc. shares recently traded at $255.64, matching the closing price on the filing date of October 22, 2026. The stock sits just 1.0% below its 52-week high of $258.30 and well above its 50-day moving average of $234.72.
Recent Earnings
The company reported trailing twelve-month revenue of $254.2 billion and earnings of $7.23 per share, backed by a net margin of 0.7%. The next earnings release is scheduled for November 5, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 2 cuts.
-
EPS & revenue
EPS beat estimates by 12.6%. Revenue missed estimates by 2.2%.
-
Profit surprise
EBITDA missed by 27 percent. Operating income missed by 46 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
2 target raises, 2 target cuts.
-
Earnings quality
Positive free cash flow.
Earnings Call Summary
Cardinal Health reported first quarter revenue of $60.9 billion, up 22 percent year over year, with earnings per share of $3.17 beating consensus of $2.80. The company saw broad strength across all five business segments, particularly in pharmaceutical specialty solutions where profit grew 26 percent and specialty drug sales benefited from GLP-1 demand growth. The strong quarter reflected execution on strategy, successful integration of acquisitions, and robust underlying pharmaceutical utilization trends across the market.
Guidance Cardinal Health raised its full year earnings guidance to between $9.65 and $9.85 per share, up 35 cents from prior guidance. The company expects Pharma profit to grow 16 to 19 percent for the year, driven by strong drug demand and the Solaris Health acquisition closing soon. Free cash flow is now guided to $3 billion to $3.5 billion for the full year, up from prior range.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Dividend
Cardinal Health pays an annual dividend of $2.06 per share, yielding 0.82% with a payout ratio of 28.3%.
Insider Buying and Selling at Cardinal Health, Inc.
Company insiders executed several transactions prior to the filing. Chief Financial Officer Aaron E. Alt sold 42,000 shares on August 18, 2026, for a total value of about $9.9 million. Officer Jessica L. Mayer sold 29,436 shares on August 18, 2026, valued at roughly $7.0 million. Chief Executive Officer Jason M. Hollar sold 124,529 shares on August 19, 2026, worth about $29.4 million. Officer Mary C. Scherer sold 2,302 shares on August 19, 2026, totaling approximately $546,473.
Analysts Set New Price Targets
Wall Street firms have updated their views on the stock. On August 13, 2026, TD Cowen maintained a Buy rating and raised its price target to $280.00 from $275.00. JP Morgan maintained a Neutral rating on August 13, 2026, while lifting its target to $260.00 from $215.00. RBC Capital initiated coverage with an Outperform rating and a $276.00 price target on August 19, 2026. UBS maintained a Buy rating and increased its target to $295.00 from $280.00 on October 16, 2026. Mizuho maintained an Outperform rating on October 20, 2026, raising its target from $250.00 to $280.00. The stock currently holds a consensus buy rating across 15 analyst opinions with a mean price target of $271.47.
About Cardinal Health
Cardinal Health, Inc. operates as a healthcare services and distribution provider, connecting pharmaceutical manufacturers with hospitals, pharmacies, and surgical centers through its extensive supply chain network. The company's performance remains closely watched by institutional investors as a bellwether for medical product distribution.
Bottom Line
Investors will look ahead to Cardinal Health's upcoming earnings report on November 5, 2026, for further updates on segment margins and distribution volume. Monitoring subsequent SEC filings will reveal whether institutional funds continue to adjust their positions in the healthcare distributor.
Related Filing Alerts
Source: Symphony Financial's 13F filing on $CAH (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts